Baseline characteristics
| Characteristic . | n (%), median (or range) . |
|---|---|
| Gender | |
| Female | 11 (50) |
| Male | 11 (50) |
| Age at transplant in years (range) | 34 (19-60) |
| Race/ethnicity | |
| Hispanic | 8 (36) |
| White | 10 (77) |
| Asian | 2 (9) |
| Black | 2 (9) |
| Stage at diagnosis | |
| I-II | 11 (50) |
| III-IV | 11 (50) |
| Disease status at transplant | |
| CR | 16 (73) |
| PR | 5 (23) |
| PD | 1 (5) |
| More than 1 line of salvage therapy | 9 (41) |
| Primary refractory to frontline therapy | 15 (68) |
| Relapse after frontline therapy | 7 (32) |
| ≤1 y | 7 |
| >1 y | 0 |
| Stage at relapse | |
| I-II | 15 (68) |
| III-IV | 7 (32) |
| B symptoms at relapse | 3 (14) |
| Extranodal disease at relapse | 8 (36) |
| Median number of high-risk factors | 2 (1-4) |
| 1 | 5 (23) |
| 2 | 10 (45) |
| 3 | 6 (27) |
| 4 | 1 (5) |
| Prior BV | 17 (77) |
| Prior PD-1 blockade | 4 (18) |
| Prior radiation therapy | 3 (14) |
| Characteristic . | n (%), median (or range) . |
|---|---|
| Gender | |
| Female | 11 (50) |
| Male | 11 (50) |
| Age at transplant in years (range) | 34 (19-60) |
| Race/ethnicity | |
| Hispanic | 8 (36) |
| White | 10 (77) |
| Asian | 2 (9) |
| Black | 2 (9) |
| Stage at diagnosis | |
| I-II | 11 (50) |
| III-IV | 11 (50) |
| Disease status at transplant | |
| CR | 16 (73) |
| PR | 5 (23) |
| PD | 1 (5) |
| More than 1 line of salvage therapy | 9 (41) |
| Primary refractory to frontline therapy | 15 (68) |
| Relapse after frontline therapy | 7 (32) |
| ≤1 y | 7 |
| >1 y | 0 |
| Stage at relapse | |
| I-II | 15 (68) |
| III-IV | 7 (32) |
| B symptoms at relapse | 3 (14) |
| Extranodal disease at relapse | 8 (36) |
| Median number of high-risk factors | 2 (1-4) |
| 1 | 5 (23) |
| 2 | 10 (45) |
| 3 | 6 (27) |
| 4 | 1 (5) |
| Prior BV | 17 (77) |
| Prior PD-1 blockade | 4 (18) |
| Prior radiation therapy | 3 (14) |
BV, brentuximab vedotin; CR, complete response; PD, progressive disease; PD1, programmed death receptor-1; PR, partial response.